Eli Lilly and Company $LLY Stock: Asset Management One Co. Ltd. Grows Stake

Key Points

• Asset Management One increased its Eli Lilly stake by 2.2% in the third quarter to 393,048 shares valued at approximately $454.8 million. Institutional investors collectively own 82.53% of the company.
• Eli Lilly reported strong quarterly results, with revenue up 38.6% year over year to $24.4 billion and EPS of $7.48, beating analysts’ $5.68 estimate. Shares traded near their 52-week high after rising 6.5%.
• Analysts remain broadly bullish, citing accelerating Mounjaro and Zepbound demand, upgraded revenue guidance and pipeline progress; the stock has a “Moderate Buy” consensus rating and a $1,320.25 average price target.

Asset Management One Co. Ltd. boosted its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 2.2% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 393,048 shares of the company's stock after buying an additional 8,423 shares during the quarter. Eli Lilly and Company accounts for approximately 1.1% of Asset Management One Co. Ltd.'s holdings, making the stock its 15th biggest position. Asset Management One Co. Ltd.'s holdings in Eli Lilly and Company were worth $454,788,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. BlackRock Inc. grew its stake in shares of Eli Lilly and Company by 1.6% in the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company's stock worth $81,009,981,000 after acquiring an additional 1,046,558 shares during the period. State Street Corp lifted its position in Eli Lilly and Company by 1.7% during the second quarter. State Street Corp now owns 36,215,754 shares of the company's stock valued at $43,438,262,000 after purchasing an additional 605,752 shares during the period. Bank of America Corp DE purchased a new stake in Eli Lilly and Company in the second quarter worth approximately $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Eli Lilly and Company by 1.9% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company's stock worth $8,647,153,000 after purchasing an additional 137,364 shares during the last quarter. Finally, Jennison Associates LLC boosted its holdings in Eli Lilly and Company by 7.9% in the second quarter. Jennison Associates LLC now owns 5,461,416 shares of the company's stock worth $6,550,587,000 after purchasing an additional 400,538 shares during the last quarter. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Trading Up 6.5%

Shares of Eli Lilly and Company stock opened at $1,372.01 on Friday. The company's fifty day simple moving average is $1,194.34 and its 200-day simple moving average is $1,090.89. The stock has a market capitalization of $1.29 trillion, a PE ratio of 46.04, a P/E/G ratio of 1.73 and a beta of 0.46. Eli Lilly and Company has a 1-year low of $812.25 and a 1-year high of $1,408.38. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.68 by $1.80. The firm had revenue of $24.40 billion during the quarter, compared to the consensus estimate of $22.58 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company's revenue for the quarter was up 38.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $7.02 EPS. As a group, equities analysts anticipate that Eli Lilly and Company will post 33.22 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be given a $1.73 dividend. The ex-dividend date is Friday, November 13th. This represents a $6.92 annualized dividend and a yield of 0.5%. Eli Lilly and Company's dividend payout ratio (DPR) is currently 23.22%.

Insiders Place Their Bets

In other news, CAO Donald A. Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the transaction, the chief accounting officer owned 1,526 shares in the company, valued at approximately $1,808,325.26. The trade was a 56.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the transaction, the executive vice president owned 11,875 shares of the company's stock, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 13,500 shares of company stock valued at $15,958,170 over the last ninety days. 0.14% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

LLY has been the subject of a number of research reports. Citigroup boosted their target price on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company a "buy" rating in a research note on Wednesday, July 15th. Sanford C. Bernstein reaffirmed an "outperform" rating and issued a $1,450.00 price objective on shares of Eli Lilly and Company in a report on Monday. Cantor Fitzgerald upped their price objective on Eli Lilly and Company from $1,410.00 to $1,440.00 and gave the company an "overweight" rating in a research report on Thursday, October 8th. Royal Bank Of Canada reissued an "outperform" rating and issued a $1,500.00 target price on shares of Eli Lilly and Company in a report on Monday, October 12th. Finally, UBS Group set a $1,376.00 target price on Eli Lilly and Company in a research report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Eli Lilly and Company presently has an average rating of "Moderate Buy" and a consensus target price of $1,320.25.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Strong earnings and sales beat estimates. Third-quarter revenue rose 39% year over year to $24.4 billion, while adjusted EPS was $7.48 versus the roughly $5.68 analyst consensus. Reported EPS was $7.22, up from $6.21 a year earlier. Eli Lilly earnings report
• Positive Sentiment: Demand for GLP-1 drugs continues to accelerate. Mounjaro sales increased 65% to $10.7 billion, while Zepbound revenue climbed 49% to $5.35 billion. The performance reinforced expectations that Lilly can continue gaining share in the rapidly expanding diabetes and obesity markets. Eli Lilly stock jumps on Mounjaro and Zepbound earnings
• Positive Sentiment: Management sharply increased its outlook. Lilly raised 2026 revenue guidance to $91 billion-$92 billion from $85 billion-$87 billion, lifting the midpoint by $5.5 billion. The company also highlighted regulatory progress, including Mounjaro’s cardiovascular-risk indication and approval of once-weekly insulin Onswik. Eli Lilly raises revenue outlook
• Positive Sentiment: Pipeline momentum added to investor enthusiasm. Phase 3 data showed experimental retatrutide produced greater A1C reductions and more than double the weight loss of Ozempic 2 mg in adults with type 2 diabetes, strengthening Lilly’s competitive position against Novo Nordisk. Retatrutide trial results
• Neutral Sentiment: Investors should monitor the quality and durability of growth. Realized prices declined about 15%, although a 53% volume increase more than offset the pressure. Approximately $900 million of quarterly benefits came from Jardiance milestones and rebate adjustments, neither of which is expected to recur fully.
• Negative Sentiment: One-time deal-related charges and access concerns remain risks. Lilly recorded about $4.2 billion in acquired in-process R&D charges, while reports also noted a Foundayo sales miss and potential employer concerns about covering costly weight-loss drugs. These factors could pressure margins or slow future demand. Eli Lilly pricing and earnings reaction

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.